Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2022-05-05 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Farxiga HFpEF Phase III trial met primary endpoint
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 4257K' and is dated May 5, 2022. It announces high-level results from the DELIVER Phase III clinical trial for the drug Farxiga, detailing efficacy endpoints and next steps (submission for presentation and regulatory filings). The text is clearly a formal announcement disseminated via RNS (the news service of the London Stock Exchange), which is explicitly mentioned at the end. Since this is an announcement of clinical trial results and future regulatory submissions, it is not a full Annual Report (10-K), an Earnings Release (ER), or a formal Investor Presentation (IP). It is a general regulatory announcement that fits best under the 'Regulatory Filings' (RNS) category, as it is a broad disclosure made through the RNS system, rather than a specific financial report type like IR or AR.
2022-05-05 English
Ultomiris NMOSD Ph. III trial met primary endpoint
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 3777K' and is dated '05 May 2022'. It details positive results from a Phase III clinical trial (CHAMPION-NMOSD) for a drug (Ultomiris) and includes quotes from investigators and company executives. The footer explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure—a brief announcement of material news disseminated via the RNS system—is characteristic of a general regulatory announcement rather than a comprehensive report (like 10-K or IR) or a specific financial event (like ER or DIV). Since it is a broad regulatory announcement that doesn't fit the more specific categories (like DIRS, MANG, or CT), the most appropriate classification is the general regulatory filing fallback.
2022-05-05 English
IMFINZI COMBO GRANTED PRIORITY REVIEW FOR BTC
Foreign Filer Report
2022-05-04 English
Imfinzi combo granted Priority Review for BTC
Legal Proceedings Report Classification · 99% confidence The document is a press release format, indicated by the presence of 'RNS Number', the date, and the structure detailing a regulatory update regarding a drug (Imfinzi) receiving Priority Review from the FDA. It contains specific medical and regulatory terminology ('sBLA', 'Priority Review', 'Phase III trial', 'FDA action date'). This type of announcement, which communicates a significant corporate/product development that is required to be disclosed to the market, fits best under the general 'Regulatory Filings' category (RNS) as it is not a comprehensive financial report (10-K, IR), a management discussion (MDA), or a specific shareholder vote result (DVA). Although it is an announcement, it is not explicitly announcing the *publication* of a separate report, but rather the regulatory event itself, making RNS the most appropriate fit among the provided options for a general regulatory news service release.
2022-05-04 English
TOTAL VOTING RIGHTS
Foreign Filer Report
2022-05-03 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a notification filed under the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. It explicitly states the total number of voting rights (1,549,464,013) as of a specific date (30 April 2022). This type of filing, which relates to the total voting rights and capital structure for transparency purposes, aligns most closely with the definition of a general regulatory announcement or a specific filing related to share capital/voting rights. Since there is no specific code for 'Voting Rights Notification' outside of DVA (Declaration of Voting Results), and this is a routine regulatory disclosure about the total number of shares with voting rights, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a standard disclosure mandated by the exchange/regulator, rather than a specific event like a dividend (DIV) or a major shareholding change (MRQ). The presence of 'RNS Number' and the closing statement confirming RNS as the Primary Information Provider strongly supports the RNS classification.
2022-05-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.